Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

171.63USD
27 Sep 2016
Change (% chg)

$-1.90 (-1.09%)
Prev Close
$173.53
Open
$170.24
Day's High
$171.98
Day's Low
$169.50
Volume
4,798,864
Avg. Vol
2,818,139
52-wk High
$176.85
52-wk Low
$130.09

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 0.94
Market Cap(Mil.): $129,863.10
Shares Outstanding(Mil.): 748.36
Dividend: 1.00
Yield (%): 2.31

Financials

  AMGN.O Industry Sector
P/E (TTM): 17.76 42.41 36.20
EPS (TTM): 9.77 -- --
ROI: 11.53 -0.33 13.87
ROE: 25.80 -3.14 14.78

UPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study

* Amgen stock down about 1.2 pct (Adds comments from conference call, analysts, details)

11:00am EDT

FDA approves Amgen's copy of AbbVie arthritis drug Humira

WASHINGTON The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar version of AbbVie's top-selling arthritis drug, Humira.

Sep 23 2016

U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira

WASHINGTON, Sept 23 The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.

Sep 23 2016

Amgen cholesterol drug reduces arterial plaque buildup: study

Amgen Inc said on Tuesday its potent new cholesterol fighter, Repatha, met the primary and secondary goals of a study designed to show it can decrease plaque buildup in heart arteries of patients already taking widely used statin drugs, such as Lipitor.

Sep 20 2016

BRIEF-Amgen announces positive top line results from Phase 3 GLAGOV imaging study of Repatha(evolocumab)

* Intravascular ultrasound study meets primary and secondary endpoints

Sep 20 2016

Apotex cleared of infringement in copycat drug dispute with Amgen

A federal judge in Florida has ruled that Apotex Inc would not infringe an Amgen Inc patent by making copycat versions of Amgen's white-blood-cell-boosting drugs Neulasta and Neupogen.

Sep 07 2016

BRIEF-Amgen gets commercial rights from Boehringer Ingelheim

* Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational bite immuno-oncology drug for multiple myeloma

Sep 01 2016

BRIEF-Amgen and servier extend omecamtiv mecarbil collaboration

* Amgen and Servier extend omecamtiv mecarbil collaboration in chronic heart failure

Sep 01 2016

BRIEF-Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3

* Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development

Sep 01 2016

Novartis bid to sell new biosimilar crimped by U.S. court battles

* Swiss drugmaker fighting Amgen on patents, regulatory hurdles

Aug 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.